• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday

    6/18/24 9:44:27 AM ET
    $ABBV
    $ACN
    $AYI
    $CMG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate
    Real Estate
    Get the next $ABBV alert in real time by email

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

    • BMO Capital raised the price target for The Kroger Co. (NYSE:KR) from $58 to $60. BMO Capital analyst Kelly Bania upgraded the stock from Market Perform to Outperform. Kroger shares gained 1.3% to close at $51.05 on Monday. See how other analysts view this stock.
    • HC Wainwright & Co. raised the price target for Nurix Therapeutics, Inc. (NASDAQ:NRIX) from $19 to $26. HC Wainwright & Co. analyst Robert Burns maintained a Buy rating. Nurix Therapeutics shares rose 0.7% to close at $15.29 on Monday. See how other analysts view this stock.
    • JMP Securities increased Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) price target from $66 to $68. JMP Securities analyst Jonathan Wolleben maintained a Market Outperform rating. rum shares rose 27.3% to close at $33.00 on Monday. See how other analysts view this stock.
    • Stifel increased the price target for Wingstop Inc. (NASDAQ:WING) from $420 to $460. Stifel analyst Chris O’Cull maintained a Buy rating. Wingstop shares gained 4.7% to close at $417.38 on Monday. See how other analysts view this stock.
    • Baird slashed Acuity Brands, Inc. (NYSE:AYI) price target from $286 to $280. Baird analyst Timothy Wojs maintained a Neutral rating. Acuity Brands shares rose 2.7% to close at $259.23 on Monday. See how other analysts view this stock.
    • Wedbush boosted Micron Technology, Inc. (NASDAQ:MU) price target from $130 to $170. Wedbush analyst Matt Bryson maintained an Outperform rating. Micron shares gained 4.6% to close at $147.83 on Monday. See how other analysts view this stock.
    • Piper Sandler boosted the price target for AbbVie Inc. (NYSE:ABBV) from $185 to $190. Piper Sandler analyst Christopher Raymond maintained an Overweight rating. AbbVie shares gained 0.7% to close at $169.68 on Monday. See how other analysts view this stock.
    • Rosenblatt increased NVIDIA Corporation (NASDAQ:NVDA) price target from $140 to $200. Rosenblatt analyst Hans Mosesmann maintained a Buy rating. NVIDIA shares fell 0.7% to close at $130.98 on Monday. See how other analysts view this stock.
    • Mizuho cut Accenture plc (NYSE:ACN) price target from $398 to $350. Mizuho analyst Dan Dolev maintained a Buy rating. Accenture shares fell 0.4% to close at $285.53 on Monday. See how other analysts view this stock.
    • Argus Research boosted Chipotle Mexican Grill, Inc. (NYSE:CMG) price target from $3,668 to $3,888. Argus Research analyst John Staszak maintained a Buy rating. Chipotle shares closed at $3,365.46 on Monday. See how other analysts view this stock.

    Check This Out: $176M Bet On Occidental Petroleum? Check Out These 3 Stocks Insiders Are Buying

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $ACN
    $AYI
    $CMG

    CompanyDatePrice TargetRatingAnalyst
    Wingstop Inc.
    $WING
    2/10/2026$285.00Buy → Hold
    TD Cowen
    Wingstop Inc.
    $WING
    2/10/2026$325.00Strong Buy → Outperform
    Raymond James
    Chipotle Mexican Grill Inc.
    $CMG
    2/4/2026$50.00 → $48.00Outperform
    Telsey Advisory Group
    Micron Technology Inc.
    $MU
    1/23/2026$350.00 → $500.00Buy
    HSBC Securities
    Micron Technology Inc.
    $MU
    1/22/2026Outperform
    William Blair
    Accenture plc
    $ACN
    1/22/2026$313.00Buy
    Berenberg
    Wingstop Inc.
    $WING
    1/20/2026$350.00Hold → Buy
    Melius
    Micron Technology Inc.
    $MU
    1/20/2026$300.00 → $450.00Buy
    TD Cowen
    More analyst ratings

    $ABBV
    $ACN
    $AYI
    $CMG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heron Patrick J acquired 159,277 shares and bought $8,999,984 worth of shares (131,425 units at $68.48) (SEC Form 4)

    4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

    1/27/26 4:14:26 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Liu Teyin M bought $7,821,723 worth of shares (23,200 units at $337.14), increasing direct ownership by 856% to 25,910 units (SEC Form 4)

    4 - MICRON TECHNOLOGY INC (0000723125) (Issuer)

    1/15/26 7:07:13 PM ET
    $MU
    Semiconductors
    Technology

    Director Heron Patrick J bought $24,214 worth of shares (549 units at $44.11) (SEC Form 4)

    4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

    3/18/25 5:04:31 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ACN
    $AYI
    $CMG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wingstop downgraded by TD Cowen with a new price target

    TD Cowen downgraded Wingstop from Buy to Hold and set a new price target of $285.00

    2/10/26 8:00:55 AM ET
    $WING
    Restaurants
    Consumer Discretionary

    Wingstop downgraded by Raymond James with a new price target

    Raymond James downgraded Wingstop from Strong Buy to Outperform and set a new price target of $325.00

    2/10/26 8:00:55 AM ET
    $WING
    Restaurants
    Consumer Discretionary

    Telsey Advisory Group reiterated coverage on Chipotle Mexican Grill with a new price target

    Telsey Advisory Group reiterated coverage of Chipotle Mexican Grill with a rating of Outperform and set a new price target of $48.00 from $50.00 previously

    2/4/26 7:57:40 AM ET
    $CMG
    Restaurants
    Consumer Discretionary

    $ABBV
    $ACN
    $AYI
    $CMG
    SEC Filings

    View All

    Kroger Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - KROGER CO (0000056873) (Filer)

    2/9/26 4:06:01 PM ET
    $KR
    Food Chains
    Consumer Staples

    SEC Form SCHEDULE 13G filed by Kroger Company

    SCHEDULE 13G - KROGER CO (0000056873) (Subject)

    2/9/26 6:47:36 AM ET
    $KR
    Food Chains
    Consumer Staples

    SEC Form 144 filed by Chipotle Mexican Grill Inc.

    144 - CHIPOTLE MEXICAN GRILL INC (0001058090) (Subject)

    2/6/26 4:03:45 PM ET
    $CMG
    Restaurants
    Consumer Discretionary

    $ABBV
    $ACN
    $AYI
    $CMG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Accenture Appoints Rachel Frey Chief Communications Officer

    Accenture (NYSE:ACN) today announced the appointment of Rachel Frey as chief communications officer, a newly created role. Effective immediately, Frey reports to Accenture Chair and CEO Julie Sweet and joins Accenture's Global Management Committee. Frey brings more than two decades of experience in communications. In her most recent role as Accenture's global head of Corporate Communications, she strengthened the company's relationships with external audiences; developed and elevated an enhanced earned communications strategy that has strategically positioned Accenture and its leaders at the forefront of AI reinvention across every major sector and region around the world; and leveraged d

    2/11/26 10:43:00 AM ET
    $ACN
    Real Estate

    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on February 10, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 163,040 shares of common stock, 219,090 restricted stock units ("RSUs"), and 48,880 performance stock units ("PSUs") to 37 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $100.91 per share, Mirum's closing trading price on Febr

    2/10/26 10:45:00 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ACN
    $AYI
    $CMG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Van Houte Hans

    4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    2/10/26 6:09:29 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Legal Officer Ring Christine

    4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    2/10/26 5:55:00 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Hansen Gwenn

    4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    2/10/26 5:50:25 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ACN
    $AYI
    $CMG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 21, 2025 - FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease

    For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

    2/21/25 11:48:20 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ACN
    $AYI
    $CMG
    Leadership Updates

    Live Leadership Updates

    View All

    Accenture Appoints Rachel Frey Chief Communications Officer

    Accenture (NYSE:ACN) today announced the appointment of Rachel Frey as chief communications officer, a newly created role. Effective immediately, Frey reports to Accenture Chair and CEO Julie Sweet and joins Accenture's Global Management Committee. Frey brings more than two decades of experience in communications. In her most recent role as Accenture's global head of Corporate Communications, she strengthened the company's relationships with external audiences; developed and elevated an enhanced earned communications strategy that has strategically positioned Accenture and its leaders at the forefront of AI reinvention across every major sector and region around the world; and leveraged d

    2/11/26 10:43:00 AM ET
    $ACN
    Real Estate

    Kroger Appoints Greg Foran as Chief Executive Officer

    Accomplished Food Retail Leader Brings Strong Experience as Company Advances Its Growth Strategy Ron Sargent Continues as Chairman of Kroger's Board of Directors  CINCINNATI, Feb. 9, 2026 /PRNewswire/ -- The Kroger Co. (NYSE:KR) today announced its Board of Directors appointed Greg Foran as Chief Executive Officer, effective immediately. Foran will also join Kroger's Board of Directors and succeeds Ron Sargent, who served as interim CEO since March 2025. This announcement follows an extensive search process conducted by the Board to identify an innovative retail leader with a strong track record of execution at scale.

    2/9/26 7:30:00 AM ET
    $KR
    Food Chains
    Consumer Staples

    Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

    SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology and as Chief Medical Officer and interim Chief Executive Officer of Seagen Inc., has had a distinguished career in hematology and oncology and over two decades of leadership experience in drug development and commercialization. "Roger

    11/10/25 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ACN
    $AYI
    $CMG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 9:00:57 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

    SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

    11/14/24 4:37:52 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 4:21:48 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ACN
    $AYI
    $CMG
    Financials

    Live finance-specific insights

    View All

    Kroger Announces Fourth Quarter Conference Call with Investors

    CINCINNATI, Feb. 5, 2026 /PRNewswire/ -- The Kroger Co. (NYSE:KR) announced today it will host its fourth quarter 2025 earnings conference call at 8:00 a.m. ET on Thursday, March 5, 2026. Kroger's management team will comment on financial and operational results for the fourth quarter and full year 2025. The presentation will broadcast online at ir.kroger.com. Click on "Quarterly Results" to access the event. An on-demand replay of the webcast will be available at approximately 1:00 p.m. ET on Thursday, March 5, 2026.  About Kroger At The Kroger Co. (NYSE:KR), we are, across o

    2/5/26 4:15:00 PM ET
    $KR
    Food Chains
    Consumer Staples

    AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

    Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of $61.160 Billion, an Increase of 8.6 Percent on a Reported Basis and 8.5 Percent on an Operational Basis  Full-Year Global Net Revenues from the Immunology Portfolio Were $30.406 Billion, an Increase of 14.0 Percent on a Reported Basis, or 13.9 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $17.562 Billion; Global Rinvoq Net Revenues Were $8.304 Billion; Global Humira Net Revenues Wer

    2/4/26 7:48:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kroger's Board of Directors Declares Quarterly Dividend

    CINCINNATI, Jan. 30, 2026 /PRNewswire/ -- The Kroger Co.'s (NYSE:KR) Board of Directors today declared a quarterly dividend of 35 cents per share to be paid on March 1, 2026, to shareholders of record as of the close of business on February 13, 2026. The company's quarterly dividend has grown at a 13% compounded annual growth rate since it was reinstated in 2006. The company continues to expect, subject to board approval, an increasing dividend over time. Kroger's capital allocation strategy is to use its free cash flow to invest in the business to drive long-term sustainable

    1/30/26 4:30:00 PM ET
    $KR
    Food Chains
    Consumer Staples